ArticleGut and liver2023
Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls.
Article in Gut and liver, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Bacterial Extracellular Vesicles as Systemic Messengers: Integrating Their Roles in Gut-Liver-Brain Communication and Disease.Probiotics and antimicrobial proteins · 2026Review
- Gut-derived bacterial membrane vesicles in prediabetes: Vesicle composition dictates inflammatory properties.iScience · 2026Article
- From food to vesicle: nutritional influences on gut microbial inflammatory signaling.Frontiers in nutrition · 2026Review
- Bacterial extracellular vesicles in osteoarthritis: a new bridge of the gut-joint axis.Gut microbes · 2025Review
- Bacterial extracellular vesicles in the initiation, progression and treatment of atherosclerosis.Gut microbes · 2025Review
- Distinct microbial signatures of liquid biopsy samples during gastric carcinogenesis and insights from extracellular vesicle analysis.The Korean journal of internal medicine · 2025Article
- Gut microbiota-derived extracellular vesicles form a distinct entity from gut microbiota.mSystems · 2025Article
- Gut microbiome-derived bacterial extracellular vesicles in patients with solid tumours.Journal of advanced research · 2025Article
- Specific Bacterial Co-abundance Groups Are Associated With Inflammatory Status in Patients With Ulcerative Colitis.Journal of Crohn's & colitis · 2025Article
- Cross - Kingdom Dialogue of Microbial Messengers: Multi - Target Regulatory Mechanisms and Therapeutic Strategies of Gut Microbiota - Derived Extracellular Vesicles in Metabolic Diseases.International journal of nanomedicine · 2025Review
- Investigating the Immunomodulatory Impact of Fecal Bacterial Membrane Vesicles and Their IgA Coating Patterns in Crohn's Disease Patients.International journal of molecular sciences · 2024Article
- Gut microbiome related to metabolic diseases after moderate-to-vigorous intensity exercise.Journal of exercise science and fitness · 2024Article
- Metformin modifies plasma microbial-derived extracellular vesicles in polycystic ovary syndrome with insulin resistance.Journal of ovarian research · 2024Article
- Gut microbiome signature of metabolically healthy obese individuals according to anthropometric, metabolic and inflammatory parameters.Scientific reports · 2024Article
- Current Knowledge and Future Perspectives of Exosomes as Nanocarriers in Diagnosis and Treatment of Diseases.International journal of nanomedicine · 2023Review
- Bacterial membrane vesicles in the pathogenesis and treatment of inflammatory bowel disease.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: This study aimed to evaluate the potential of the stool microbiome and gut microbe-derived extracellular vesicles (EVs) to differentiate between patients with inflammatory bowel disease (IBD) and healthy controls, and to predict relapse in patients with IBD. Methods: Metagenomic profiling of the microbiome and bacterial EVs in stool samples of controls (n=110) and patients with IBD (n=110) was performed using 16S rRNA sequencing and then compared. Patients with IBD were divided into two enterotypes based on their microbiome, and the cumulative risk of relapse was evaluated. Results: There was a significant difference in the composition of the stool microbiome and gut microbe-derived EVs between patients with IBD and controls. The alpha diversity of the microbiome in patients with IBD was significantly lower than that in controls, while the beta diversity also differed significantly between the two groups. These findings were more prominent in gut microbe-derived EVs than in the stool microbiome. The survival curve tended to be different for enterotypes based on the gut microbe-derived EVs; however, this difference was not statistically significant (log-rank test, p=0.166). In the multivariable analysis, elevated fecal calprotectin (>250 mg/kg) was the only significant risk factor associated with relapse (adjusted hazard ratio, 3.147; 95% confidence interval, 1.545 to 6.408; p=0.002). Conclusions: Analysis of gut microbe-derived EVs is better at differentiating patients with IBD from healthy controls than stool microbiome analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.